CD5 CAR T-cells

Developed for: T-cell acute lymphoblastic leukemia · mature T-cell and NK-cell non-Hodgkin lymphoma · T-cell and NK-cell neoplasm · T-lymphoblastic lymphoma
Investigated by: Beijing GoBroad Hospital · Shanghai Liquan Hospital · Yake Biotechnology Ltd. · Zhejiang University · Central People's Hospital of Zhanjiang · First Affiliated Hospital of Guangxi Medical University
+3 more
· Ruijin Hospital · The General Hospital of Western Theater Command · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT06633341	Oct 2024 → Oct 2027 expected	T-lymphoblastic lymphoma	Zhejiang University	Recruiting	No outcome recorded
Phase 0	NCT06633354	Oct 2024 → Oct 2027 expected	T-cell acute lymphoblastic leukemia	Zhejiang University	Recruiting	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT07022964	Jun 2025 → Jun 2026 overdue	mature T-cell and NK-cell non-Hodgkin lymphoma	Beijing GoBroad Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT06316856	Jun 2024 → Jun 2026 overdue	T-cell acute lymphoblastic leukemia, T-cell and NK-cell neoplasm	Beijing GoBroad Hospital	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	CD5 CAR T-cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06633341 ↗ 3 NCT06633354 ↗ NCT06316856 ↗ NCT07022964 ↗
Modality	Cell therapy	“anti-CD5 CAR-T cell therapy” NCT06316856 ↗
Route	Intravenous	“by intravenous infusion” NCT06633341 ↗
Target	CD5	“CD5 CAR T-cell infusion” NCT06316856 ↗